Shares of Ardelyx (NASDAQ: ARDX) surged over 6% in extended trading on Tuesday after the biotechnology company reported impressive third-quarter financial results that topped Wall Street's expectations.
Ardelyx posted quarterly sales of $98.24 million, marking a 74.21% year-over-year increase and exceeding the analyst consensus estimate of $86.64 million by a staggering 13.39%. The strong revenue performance was a major positive surprise for investors, driving the stock's substantial after-hours rally.
While the company has yet to provide full details on its earnings and guidance, the sizable top-line beat suggests Ardelyx's business momentum remains robust. Investors will be keen to learn more about the key drivers behind the better-than-expected sales figures during the company's earnings call.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。